Literature DB >> 3932051

A multicenter international controlled comparison of two dosage regimes of misoprostol and cimetidine in the treatment of duodenal ulcer in out-patients.

P A Nicholson.   

Abstract

In this double-blind parallel group multicenter international study, patients with endoscopically proven acute duodenal ulcers were allocated randomly to treatment for four weeks with either misoprostol 50 micrograms, misoprostol 200 micrograms or cimetidine 300 mg, each given q.i.d.. Endoscopic, clinical and laboratory assessments were made prior to and after four weeks' treatment. A clinical assessment was also made at two weeks. 703 patients were recruited. The three treatment groups were similar with regard to age, sex and occupation. Therapeutic success was defined as complete healing of all ulcers on the basis of an endoscopic examination. On an intent to treat basis, which includes all losses to follow-up and withdrawals as treatment failures, the cure rates in the misoprostol 50 micrograms, misoprostol 200 micrograms and cimetidine groups were 41%, 60% and 67% respectively. There was no statistically significant difference between the misoprostol 200 micrograms and the cimetidine 300 mg groups (P = 0.11). Both were significantly better than the low dose misoprostol group (P less than 0.001). All three treatments were well tolerated and severe adverse events were rare.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932051     DOI: 10.1007/bf01309405

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  7 in total

1.  Interim results of a multicenter international comparison of misoprostol and cimetidine in the treatment of out-patients with benign gastric ulcers.

Authors:  M J Shield
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

2.  The effect of 16,16-dimethyl prostaglandin E2 on meal-stimulated gastric acid secretion and serum gastrin in duodenal ulcer patients.

Authors:  A F Ippoliti; J I Isenberg; V Maxwell; J H Walsh
Journal:  Gastroenterology       Date:  1976-04       Impact factor: 22.682

3.  Effect of 15(R)-15-methyl prostaglandin E2 (arbaprostil) on the healing of duodenal ulcer: a double-blind multicenter study.

Authors:  G Vantrappen; J Janssens; T Popiela; J Kulig; G N Tytgat; K Huibregtse; R Lambert; J P Pauchard; A Robert
Journal:  Gastroenterology       Date:  1982-08       Impact factor: 22.682

Review 4.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

5.  Double-blind clinical trial on gastroduodenal ulcer healing with prostaglandin E2 analogues.

Authors:  K Gibiński; J Rybicka; E Mikoś; A Nowak
Journal:  Gut       Date:  1977-08       Impact factor: 23.059

6.  Ranitidine heals duodenal ulcers.

Authors:  I N Marks; J P Wright; M Denyer; A Hatfield; A H Girdwood; W Lucke
Journal:  S Afr Med J       Date:  1982-01-30

7.  Treatment of duodenal ulcer with ranitidine, a new histamine H2-receptor antagonist.

Authors:  A Berstad; K Kett; E Aadland; E Carlsen; K Frislid; K Saxhaug; A Kruse-Jensen
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423

  7 in total
  12 in total

Review 1.  Histamine H2-receptor antagonists versus prostaglandins in the treatment of peptic ulcer disease.

Authors:  J G Penston; K G Wormsley
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

2.  Effect of enprostil on amphibian gastroduodenal and human gastric bicarbonate secretion.

Authors:  C J Shorrock; L C Gibbons; W D Rees
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

3.  A multicenter international controlled comparison of two dosage regimens of misoprostol with cimetidine in treatment of gastric ulcer in outpatients.

Authors:  D Rachmilewitz; J W Chapman; P A Nicholson
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

4.  Overview of clinical safety with misoprostol.

Authors:  R L Herting; G A Clay
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

5.  Effect of misoprostol on histamine-stimulated acid secretion and cyclic AMP formation in isolated canine parietal cells.

Authors:  B S Tsai; L K Kessler; G M Butchko; R F Bauer
Journal:  Dig Dis Sci       Date:  1987-09       Impact factor: 3.199

Review 6.  Review of the safety of diclofenac/misoprostol.

Authors:  P Gagnier
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Prostaglandins in peptic ulcer disease. An overview of current status and future directions.

Authors:  S J Sontag
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

8.  Effect of chronic misoprostol ingestion on rat gastric morphology and cell turnover.

Authors:  A Fich; N Arber; E Okon; G Zajicek; D Rachmilewitz
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

9.  The role of arachidonic acid metabolites in gastrointestinal homeostasis. Biochemical, histological and clinical gastrointestinal effects.

Authors:  K J Isselbacher
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease.

Authors:  C K Ching; S K Lam
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.